Aspire Capital Fund SC 13G Akari Therapeutics / Aspire Capital Fund ownership change

Exhibit 99.1

JOINT FILING AGREEMENT

In accordance with Rule13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the persons named below agrees to the joint filing of a Statement on Schedule 13G (including amendments thereto) with respect to the shares of Ordinary Shares, par value £0.01 per share, of Akari Therapeutics, Plc, and further agree that this Joint Filing Agreement shall be included as an exhibit to such joint filings.

This Joint Filing Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts together shall constitute one agreement.

In evidence thereof, the undersigned, being duly authorized, hereby execute this Joint Filing Agreement as of July 2, 2020.

ASPIRE CAPITAL FUND, LLC BY: ASPIRE CAPITAL PARTNERS, LLC BY: SGM HOLDINGS CORP.		ASPIRE CAPITAL PARTNERS, LLC BY: SGM HOLDINGS CORP.
By:	/s/ Steven G. Martin	By:	/s/ Steven G. Martin
Name:	Steven G. Martin	Name:	Steven G. Martin
Title:	President	Title:	President
SGM HOLDINGS CORP.		RED CEDAR CAPITAL CORP.
By:	/s/ Steven G. Martin	By:	/s/ Erik J. Brown
Name:	Steven G. Martin	Name:	Erik J. Brown
Title:	President	Title:	President
CHRISKO INVESTORS, INC.		WML VENTURES CORP.
By:	/s/ Christos Komissopoulos	By:	/s/ William F. Blank III
Name:	Christos Komissopoulos	Name:	William F. Blank III
Title:	President	Title:	President
STEVEN G. MARTIN		ERIK J. BROWN
/s/ Steven G. Martin		/s/ Erik J. Brown
CHRISTOS KOMISSOPOULOS		WILLIAM F. BLANK III
/s/ Christos Komissopoulos		/s/ William F. Blank III